Evidence map›Paper›PMID 36131622›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus.

Ningning Cheng, Nan Jiang, Yuanhui Fu, Zhuxin Xu, Xianglei Peng, Jiemei Yu, Shan Cen, Yucheng Wang, Guoning Zhang, Yanpeng Zheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ningning ChengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Nan JiangCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Yuanhui FuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Zhuxin XuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Xianglei PengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Jiemei YuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Shan CenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yucheng WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Guoning ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yanpeng ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Jinsheng HeCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection worldwide. Until now, there are no licenced vaccines or effective antiviral drugs against RSV infections. In our previous work, we found 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivatives (4-49 C and 1-HB-63) being a novel inhibitor against RSV

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsAcetamidesAmidesAnimalsAntiviral AgentsHumansMiceMice, Inbred BALB CVirus ReplicationAcetamidesAmidesAntiviral Agents2-((1H-indol-3-yl)thio/ sulfinyl)-N-pheny acetamide derivativeantiviral mechanismin vivo imagingpharmacodynamicsrespiratory syncytial virus

Identifiers

PMID36131622
PMCPMC9518288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.